Antisense & RNAi Therapeutics Market Report 2025

The antisense & RNAi therapeutics market size has grown rapidly in recent years. It will grow from $1.75 billion in 2024 to $1.94 billion in 2025 at a compound annual growth rate (CAGR) of 11.2%. The growth in the historic period can be attributed to a rise in funding, advancement in technologies, and rise in healthcare expenditure, rapid growth in the elderly population, and economic growth in emerging markets.

The antisense & RNAi therapeutics market size is expected to see rapid growth in the next few years. It will grow to $3.18 billion in 2029 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to an increase in healthcare access, rising prevalence of cancer, and increasing demand for antisense and RNAi therapeutics due to COVID-19. Major trends in the forecast period include focus efforts towards the research and development of RNA therapeutics for orphan diseases, use of nanoparticles, development of new and improved antisense and RNAi therapeutics, and collaboration with other companies for product innovation and to drive revenues.

The increasing prevalence of coronary artery diseases, neurodegenerative disorders, and infectious diseases is expected to boost demand for the antisense and RNAi therapeutics market. Gene suppression techniques, such as RNA interference and antisense oligonucleotides, are utilized to treat various neurodegenerative conditions by repairing mutant genes. For example, a report from the American Heart Association, a U.S.-based organization, published in January 2024, indicated that the age-adjusted death rate from cardiovascular diseases rose to 233.3 per 100,000, marking a 4% increase from the previous year. Therefore, the growing incidence of neurodegenerative and infectious diseases is anticipated to drive the growth of the antisense and RNAi therapeutics market.

The increasing prevalence of chronic diseases is expected to drive demand for the antisense and RNAi therapeutics market. Chronic diseases are long-term health conditions that cannot be cured, encompassing illnesses such as cardiovascular diseases, oncological disorders, and others. Antisense and RNA interference (RNAi) therapeutics have demonstrated potential in treating various cardiovascular diseases by targeting specific genes or molecular pathways linked to the pathogenesis of these conditions. For example, the World Heart Report 2023, published by the World Health Organization (WHO), a U.S.-based specialized agency, revealed that in 2021, approximately 20.5 million individuals died from cardiovascular conditions, accounting for roughly one-third of all global deaths that year. Therefore, the rising prevalence of chronic diseases is anticipated to propel the growth of the antisense and RNAi therapeutics market.

Major companies in the antisense & RNAi therapeutics sector are employing strategic collaborations and partnerships as key initiatives to maintain their positions in an increasingly competitive market landscape. These partnerships involve joint efforts between two or more companies aiming to achieve shared objectives. For instance, in January 2023, Orbit Discovery Limited, a US-based company specializing in peptide discovery services, teamed up with SanegeneBio Inc., a UK-based firm focused on developing innovative RNAi-based medicines. This collaboration aims to identify tissue-specific delivery of RNA therapeutics for efficient gene knockdown. The partnership involves hit identification and cell-based internalization studies, leveraging Orbit's proprietary technology for rapid peptide lead discovery. Sanegene gains the opportunity to further develop potential hits derived from the screening activities for advanced RNAi therapeutics.

Major players in the antisense & RNAi therapeutics market are fostering partnerships to forge new relationships aimed at jointly creating innovative products. These strategic collaborations represent cooperative alliances between organizations, pooling their strengths or resources toward common goals. For example, in December 2022, GlaxoSmithKline (GSK), a UK-based pharmaceutical giant, and Wave Life Sciences, a US-based company specializing in genetic medicines, announced a collaboration to develop oligonucleotide therapeutics targeting novel genetic markers. By integrating GSK's genetic expertise with Wave's PRISM platform, the collaboration aims to advance up to eight preclinical programs. Additionally, GSK secures an exclusive global license for Wave's WVE-006, a potential RNA editing program targeting alpha-1 antitrypsin deficiency (AATD). Wave's PRISM platform uniquely offers three RNA-targeting modalities, leveraging innovative chemistry to optimize the properties of therapeutic oligonucleotides.

In July 2023, Alnylam, a U.S.-based biopharmaceutical company specializing in RNAi therapeutics, announced a strategic partnership with Roche, a Switzerland-based global healthcare company that develops medicines, diagnostics, and treatments. The partnership involves an initial investment of $310 million, with the total deal value potentially reaching up to $2.8 billion through various development, regulatory, and sales milestones. As part of this collaboration, the companies will co-develop and co-commercialize Zilebesiran, an investigational RNAi therapeutic aimed at treating hypertension in patients at high cardiovascular risk. This partnership combines Alnylam's expertise in RNAi therapeutics with Roche's extensive experience in drug development and commercialization, potentially transforming treatment options for patients with hypertension and high cardiovascular risk.

Major companies operating in the antisense & RNAi therapeutics market include Biogen Inc., Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Moderna Inc., Sanofi S.A., Dicerna Pharmaceuticals Inc., Arbutus Biopharma Corporation, Acuitas Therapeutics, Adhera Therapeutics Inc., EdiGene Inc., Sirnaomics Inc., Suzhou Ribo Life Science Co. Ltd, Biocon Limited, Quark Pharmaceuticals, GlaxoSmithKline Plc, Shanghai Junshi Biosciences Co. Ltd., AstraZeneca, Benitec Biopharma Limited, Silence Therapeutics, Dynacure, CN Bio Innovations, Sarepta Therapeutics, Mallinckrodt, Regeneron Pharmaceuticals Inc., Alcyone Lifesciences Inc., Bio-Path Holdings Inc, Calando Pharmaceuticals, Enzon Pharmaceuticals Inc, Celnova Pharma, Pfizer Inc., Taiba Pharma, Gen İlaç ve Sağlık Ürünleri A.Ş., Egypt Otsuka Pharmaceutical.

North America was the largest region in the antisense & RNAi therapeutics market in 2024. The regions covered in the antisense & RNAi therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antisense & RNAi therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

Antisense therapy involves the targeted and sequence-specific suppression of gene expression using single-stranded DNA oligonucleotides. In contrast, RNA interference (RNAi) is triggered by double-stranded RNA (dsRNA) and leads to the sequence-specific degradation of single-stranded target RNAs.

The primary technologies in antisense and RNAi therapeutics are RNA interference and antisense RNA. RNA interference is a conserved biological response to double-stranded RNA, which plays a role in resisting both endogenous parasitic and exogenous pathogenic nucleic acids, and it regulates the expression of protein-coding genes. Various routes of administration for these therapies include pulmonary delivery, intravenous injections, intra-dermal injections, intraperitoneal injections, topical delivery, and other methods. These therapies are used for indications such as oncology, cardiovascular diseases (CVDs), respiratory disorders, neurological disorders, infectious diseases, and others.

The antisense & RNAi therapeutics market research report is one of a series of new reports that provides antisense & RNAi therapeutics market statistics, including antisense & RNAi therapeutics industry global market size, regional shares, competitors with antisense & RNAi therapeutics market share, detailed antisense & RNAi therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the antisense & RNAi therapeutics industry. This antisense & RNAi therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The antisense and RNAi therapeutics market includes revenues earned by entities by regulating gene expression at multiple levels, such as at replication, transcription, and translation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.